Taifun® B אסטוניה - אסטונית - Adama

taifun® b

adama - vesilahus - glüfosaat - herbitsiidid

Gusto® אסטוניה - אסטונית - Adama

gusto®

adama - graanulid - metaldehüüd - molluskitsiidid

Mirador® Xtra אסטוניה - אסטונית - Adama

mirador® xtra

adama - suspensioonikontsentraat - asoksüstrobiin + tsüprokonasool - fungitsiidid

Trimmer® 50 SG אסטוניה - אסטונית - Adama

trimmer® 50 sg

adama - vees dispergeeruvad graanulid - tribenuroon-metüül - herbitsiidid

Ontilyv האיחוד האירופי - אסטונית - EMA (European Medicines Agency)

ontilyv

bial portela & companhia s.a. - opikapoon - parkinsoni tõbi - parkinsoni tõve ravimid - ontilyv is indicated as adjunctive therapy to preparations of levodopa/ dopa decarboxylase inhibitors (ddci) in adult patients with parkinson’s disease and end-of-dose motor fluctuations who cannot be stabilised on those combinations.

Invokana האיחוד האירופי - אסטונית - EMA (European Medicines Agency)

invokana

janssen-cilag international nv - canagliflozin - suhkurtõbi, tüüp 2 - diabeetis kasutatavad ravimid - invokana is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise:as monotherapy when metformin is considered inappropriate due to intolerance or contraindicationsin addition to other medicinal products for the treatment of diabetes. for study results with respect to combination of therapies, effects on glycaemic control, cardiovascular and renal events, and the populations studied, see sections 4. 4, 4. 5 ja 5.

Jardiance האיחוד האירופי - אסטונית - EMA (European Medicines Agency)

jardiance

boehringer ingelheim international gmbh - empagliflozin - diabetes mellitus, type 2; heart failure; renal insufficiency, chronic - diabeetis kasutatavad ravimid - type 2 diabetes mellitusjardiance is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exerciseas monotherapy when metformin is considered in addition to other medicinal products for the treatment of diabetesfor study results with respect to combinations of therapies, effects on glycaemic control, and cardiovascular and renal events, and the populations studied, see sections 4. 4, 4. 5 ja 5. of the annex. heart failurejardiance is indicated in adults for the treatment of symptomatic chronic heart failure.  chronic kidney diseasejardiance is indicated in adults for the treatment of chronic kidney disease.

Trulicity האיחוד האירופי - אסטונית - EMA (European Medicines Agency)

trulicity

eli lilly nederland b.v. - dulaglutiidi - suhkurtõbi, tüüp 2 - drugs used in diabetes, blood glucose lowering drugs, excl. insulins - trulicity is indicated for the treatment of patients 10 years and above with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exerciseas monotherapy when metformin is considered inappropriate due to intolerance or contraindicationsin addition to other medicinal products for the treatment of diabetes. uuringu tulemused seoses kombinatsioonid, mõju glycaemic kontrolli ja kardiovaskulaarsete sündmuste ja elanikkonna uuritud, vt punktid 4. 4, 4. 5 ja 5.

Suliqua האיחוד האירופי - אסטונית - EMA (European Medicines Agency)

suliqua

sanofi winthrop industrie - insuliini glargine, lixisenatide - suhkurtõbi, tüüp 2 - diabeetis kasutatavad ravimid - suliqua is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus to improve glycaemic control as an adjunct to diet and exercise in addition to metformin with or without sglt-2 inhibitors.